Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.37 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1088765 | 0.76 | KDM4E (0.42) | GPR119HPGDRECQLEPHX1KDM4E | |
| SCHEMBL19083252 | 0.76 | SLC6A1 (0.36) | — | |
| SCHEMBL6003485 | 0.75 | HPGD (0.46) | GPR119HPGDRECQLEPHX1KDM4E | |
| SCHEMBL31697753 | 0.75 | GPR119 (0.43) | GPR119HPGDRECQLEPHX1KDM4E | |
| SCHEMBL23267860 | 0.75 | HPGD (0.48) | GPR119HPGDRECQLEPHX1KDM4E | |
| SCHEMBL14497234 | 0.75 | GPR119 (0.50) | GPR119HPGDRECQLEPHX1KDM4E | |
| SCHEMBL15000860 | 0.75 | GNAI3 (0.51) | GPR119HPGDRECQLEPHX1KDM4E | |
| SCHEMBL5240935 | 0.74 | CNR1 (0.43) | HPGDRECQLEPHX1KDM4EMAPT | |
| SCHEMBL30706198 | 0.74 | CNR1 (0.43) | HPGDRECQLEPHX1KDM4EMAPT | |
| SCHEMBL25572001 | 0.74 | CNR1 (0.43) | HPGDRECQLEPHX1KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7884099-B2 | such as (R)-5'-[3-{1-(4-{1-[1-(3-Carboxy-1-cyclopropyl-7-fluoro-9-methyl-4-oxo-4H-quinolizine-8-yl)-pyrrolidin-3-yl-cyclopropyl]-methylamino}-piperidin-1-yl]-3'-hydroxy-benzoxazinorifamycin, useful as bactericides for the treatment of bacterial infections | CUMBRE IP VENTURES, L.P. (US) | 2011-02-08 | — | — | US | disclosed |
| US-20090143373-A1 | QUINOLONE CARBOXYLIC ACID-SUBSTITUTED RIFAMYCIN DERIVATIVES | CUMBRE PHARMACEUTICALS INC. (US) | 2009-06-04 | — | — | US | disclosed |
| WO-2009064792-A1 | QUINOLONE CARBOXYLIC ACID-SUBSTITUTED RIFAMYCIN DERIVATIVES | CUMBRE PHARMACEUTICALS INC. (US) | 2009-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143373-A1 | QUINOLONE CARBOXYLIC ACID-SUBSTITUTED RIFAMYCIN DERIVATIVES | NQO2, SDHA, QPCT | GPR119 2866/4885HPGD 331/4885RECQL 864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.